trial have not been made clear to me in this publication as it stands. My concerns are as follows:
The primary purpose of the trial is unclear to me from the background and description of the outcomes. Need more background on why this trial is needed. A lot of institutions have standardized protocols similar to this. Does the use of this standard protocol improve efficacy decrease adverse events. The trial is a one arm trial and the hypothesis is unclear as written. Will it improve treatment success, perhaps it would be better to study adherence? I guess I am a little confused
The authors contradict their own statement in that they are implementing a standard protocol while also stating there is insufficient evidence for consensus on a protocol. Unclear specifically how this trial adds to previous studies based on the current presentation… the purpose of this single arm trial is to establish the baseline efficacy of this standard protocol. Was the protocol consensus based. Did the authors use available evidence. Where did the protocol come from?
How did they come up with sample size? The power given doesn"t make sense without a context of what outcome they are powering on. State this clearly. Is it for example power to detect within 18.5% on either side of success of termination of SVT based on the trial efficacy?? Based on what expected success rate?
Other minor points: Authors need to give more info on why using AV intervals to determine therapy in the manuscript rather than just in the protocol and provide citations for this.
Intro is a little all over the place Line 17 do the authors mean "improvements in sinus rhythm" or "conversion to sinus rhythm"?
Mean heart rate <180 is not necessarily low enough. How did they choose this number?
There are a lot of secondary endpoints for a sample size of 50 patients Define ECG abnl (any abnormality, lengthening of QT with sotalol is normal but there is an acceptable limit) Not sure neonatal adverse event should be an arrhythmia as some infants will go back into SVT after separated from mom and placental therapy and this is expected rather than an adverse outcome from the trial.
A lot of leeway with exclusion criteria, P11 line 6 Need to be more specific in describing AV interval measurement. Need to be more specific in descrpitions Line 13 belongs in exclusion Do the patients have to wait until registration to receive therapy?? How long does this take?
Confused by pate 13 line6. Does that mean if therapy continues if not effective or in generally does the protocol cover adjustments based on dose or are these up to provider discretion.
The criteria for delivery seems very non specific. If they are measuring premature delivery as an outcome this should be more specific.
VERSION 1 -AUTHOR RESPONSE
# Reviewer: 1 Question 1 The criterion of fetal arrhythmia is sustained tachycardia more than 180 bpm. This definition might include some cases of sinus tachycardia. More references about rate of fetal arrhythmia should be addressed for this definition. Response: The authors cannot change this definition since this study is already started with this inclusion criteria. Authors agree your comment that fetal arrhythmia with 1: 1 atrioventricular conduction at rates of 180 to 200 bpm might include some cases of sinus tachycardia such as infection, anemia, fetal distress, medication use, trauma, or hyperthyroidism in the mother (e.g., see Clin Perinatol 2005; 32:891-912. / Clin Perinatol 2007; 34:627-652.) Prenatal feature of the sinus tachycardia is very similar to atrial ectopic tachycardia with a gradual increase or decrease in fetal heart rate, lack of abrupt initiation or breaks and preserved heart rate variability in the setting of 1: 1 atrioventricular conduction with long VA interval. Some of the fetuses with the sinus tachycardia may excluded by the definition of "sustained tachycardia" when present ≥ 50% during a 40-minute fetal heart rate monitoring or 30-minute echocardiography session, but some cases with sinus tachycardia definitely have chance to be included in this study. However, it is one of our purpose to do this study to clarify the incidence of type of tachycardia with this definition of fetal tachycardia. Therefore, this study may answer this question. In accordance with the reviewer"s suggestion, the authors have added the following sentences (page 5, lines 4-6), "Fetal arrhythmia with 1: 1 atrioventricular conduction at rates of 180 to 200 bpm might include some cases of sinus tachycardia such as infection, anemia, fetal distress, medication use, trauma, or hyperthyroidism in the mother.1, 2" Question 2 For the neurodevelopment outcome, Kyoto scale was considered to be used in this study. However, it is not a widely-accepted scale such as Bayley scales of infant development. This may have negative effect on the external validity for this trial. Response: The authors totally agree for the reviewer"s comment. Since the results of this trial should be informative internationally, the neurodevelopment outcome assessed by Kyoto scale, Japanese local method, may have negative effect for this trial. However, the other methods such as Bayley III scale are not widely used in Japan. Since the neurodevelopment outcome is one of the very important secondary endpoints, Kyoto scale, widely used all over Japan, is the only choice to accept in this trail to collect more data. In addition, the result of Kyoto scale is reported to be well correlated to Bayley III scale for the neurodevelopment follow-up in the cases with very low birth infant. The results of the two tests cannot be equally compared because the definition of the scales of Kyoto scale differs from that of Bayley III and they do not measure the exact same function. However, each DQ of Kyoto scale strongly correlated with the corresponding composite score of Bayley III. Overall DQ of Kyoto scale was also highly associated with the composite scores with coefficients of correlation of more than 0.55 (see Brain Dev 2016; 38:377-85.) . Therefore, the authors added the following sentences (page 16, line 24-page 17, line 3), "Kyoto scale, standardized neurodevelopment assessment method in Japan, is reported to be well correlated to Bayley III scale for the neurodevelopment follow-up in the cases with very low birth infant. The motor, cognitive, and language scores, which are representing specific areas in child development, correlated well between the two tests.18" # Reviewer: 2 Question 1 The primary purpose of the trial is unclear to me from the background and description of the outcomes. Need more background on why this trial is needed. A lot of institutions have standardized protocols similar to this. Does the use of this standard protocol improve efficacy decrease adverse events? The trial is a one arm trial and the hypothesis is unclear as written. Will it improve treatment success, perhaps it would be better to study adherence? I guess I am a little confused. Response: With reviewing many of previous reports, the authors reached the points that there had been no protocol to be proved the efficacy and the incidence of adverse events by the multicenter prospective study. In order to develop clinical guidelines for safe and effective fetal tachyarrhythmia treatment, as written in primary goal of this study, the authors need the clear results of efficacy and the incidence of adverse events by the multicenter prospective study. To clarify this point, the authors revised the introduction as following (page 6, lines 1-9), "Although a lot of institutions have reported standardized protocols, majority of reports are single-center retrospective studies. These reports have limitation in design, including institution biases and differences in the inclusion or exclusion criteria. In addition, many of the retrospective studies are difficult to collect maternal, fetal and neonatal adverse events. To the best of our knowledge, there are only two prospective studies.10, 11 However, these are single-center and relatively small sample size which is less than 20 cases. Therefore, we are now performing the larger multicenter prospective study to confirm the efficacy and safety of the protocoldefined transplacental treatment of fetal tachyarrhythmias." Question 2 The authors contradict their own statement in that they are implementing a standard protocol while also stating there is insufficient evidence for consensus on a protocol. Unclear specifically how this trial adds to previous studies based on the current presentation… the purpose of this single arm trial is to establish the baseline efficacy of this standard protocol. Was the protocol consensus based? Did the authors use available evidence? Where did the protocol come from? Response: In Japan, as in many other countries, many fetal centers had had their own standard protocol to treat fetal tachyarrhythmia based on the previous reports. However, the protocols are so different in each center and some of the protocols seems to be suboptimal, hence, the authors found it very important to make a guideline. On that process to make it, the authors reached the point that there had been no protocol to be proved the efficacy and the incidence of adverse events by the multicenter prospective study, as explained above question. To make this study protocol, the authors reviewed multiple previous papers, and compared different protocols in each paper. Authors added the following sentences to summarized the reasons to reach this protocol (page 6, lines 10-21), "The choice of first-and second-line antiarrhythmic therapy and criteria for decisions about management after initial treatment failure are controversial. In many centers, digoxin, administered maternally either orally or intravenously, is used as first-choice therapy because of its relatively safe profile, its long history of use during pregnancy, and the familiarity with its use. Sotalol, flecainide and amiodarone have all been used as second-choice therapy.12-14 However, amiodarone has a more significant toxicity profile for the mother and fetus.14 Therefore, we selected digoxin as the first-choice drug, sotalol as the second-choice drug, and flecainide as the third-choice drug in this study protocol. Digoxin has been explained by incomplete passage of the drug across the placenta, whereas sotalol and flecainide continue to cross the placenta readily even if there is fetal hydrops and should be preferred for patients in heart failure. Combination therapy with sotalol or flecainide is selected in hydropic fetuses." Question 3 How did they come up with sample size? The power given doesn"t make sense without a context of what outcome they are powering on. State this clearly. Is it for example power to detect within 18.5% CRC and Hall, 2007) . As you pointed out, one of the most common methods used in clinical trials is the power-based method. The precision-based method, which was used in this trial, is another common method and often used as an alternative to the power-based approach as the power-based methods may result in too sample sizes to conduct clinical trials. As described in the manuscript, the sample size of 50 subjects was determined to provide ClopperPearson exact 95% confidence interval with a width equal to 18.5 when the proportion of disappearance of fetal tachyarrhythmias was assumed 90%, using the precision-based method. Let P0 and P1 be the proportions of disappearance of fetal tachyarrhythmias under the null and the alternative hypotheses, respectively, and in our study, P0=0.8 and P1=0.9 were assumed. When testing the null hypothesis P1≤P0 versus the alternative hypothesis P1>P0, under this sample size, the null hypothesis can be rejected at the significant level of 0.025 (an actual size of the test is 0.0185) for one-sided exact binominal test if the number of subjects with the disappearance of fetal tachyarrhythmias is greater than or equal to 46. As mentioned above, our sample size can provide a good precision in estimating the proportion of disappearance of fetal tachyarrhythmias and adequately control the Type I error rate in conducting the hypothesis testing. However, generally a result derived from small clinical trials may not be robust. Therefore, we will plan to conduct sensitivity analysis to evaluate the robustness of conclusion from our study.
Question 4
Authors need to give more info on why using AV intervals to determine therapy in the manuscript rather than just in the protocol and provide citations for this. Response: In accordance with the reviewer"s suggestion, the authors have changed to the following sentences (page 6, line 22-page 7, line 8). "The precise identification of the mechanism underlying a tachyarrhythmia is important since the pharmacological approach can be quite different. It is important to give the most efficient drug at the lowest possible dose and to avoid as much as possible blind trials of multiple drugs that increase the risk of maternal and fetal morbidity. To classify tachyarrhythmia, the efficacy of atrioventricular (AV) and ventriculoatrial (VA) intervals based on Doppler echocardiography is reported.11, 15, 16 Short VA SVT is the typical pattern in atrioventricular reentrant tachycardia. All drugs can be expected to be effective against the majority of re-entrant tachycardia found in utero. In this study protocol, digoxin is used as first-choice therapy because of the vast experience gained with this agent in prenatal antiarrhythmic treatment. On the other hand, long VA SVT is rare tachycardia, suggesting atrial ectopic tachycardia or permanent junctional reciprocating tachycardia. Since digoxin was reported to be ineffective in the long VA SVT,17 sotalol is used as first-choice therapy in this study protocol."
Question 5
Intro is a little all over the place. Response: In accordance with the reviewer"s suggestion, the authors removed the following sentences and shorted the Introduction, "The concept of "fetal therapy" is spreading into many areas of fetal medicine, where researchers are revisiting conventional treatment protocols based on clinical evidence collected from randomized controlled trials. The emerging medical system that views the embryo or fetus as a distinct being from the mother is not compatible with the current health care program, whose basic idea is that "the fetus is part of the mother"s body." Under these circumstances, several research groups focusing on fetal therapy have applied for coverage under the Japanese Advanced Investigational Medical Care Evaluation Program. As this clinical study is expected to help establish a new medical treatment for fetal pathology, this study has also applied for coverage under the Japanese Advanced Investigational Medical Care Evaluation B Program." Question 6 Page 5, line 17. Do the authors mean "improvements in sinus rhythm" or "conversion to sinus rhythm"? Response: In accordance with the reviewer"s suggestion, the authors have corrected to the following sentence (page 5, lines 19). "It has long been known that administration of antiarrhythmic drugs in a pregnant woman with fetal tachyarrhythmia have improvements in sinus rhythm of her fetus, and efforts have been made for transplacental treatment."
Question 7
Mean heart rate <180 is not necessarily low enough. How did they choose this number? Response: The goal of treatment is not conversion to 100% of sinus rhythm but rather establishment of resolution of hydrops and/or ventricular dysfunction. As reported in many previous studies, fetal hydrops may resolve by lowing ventricular rates and returning triphasic flow in the ductus venosus, even in the absence of sustained sinus rhythm. Since increasing the doses or adding other antiarrhythmic drug may have some chance to increase the adverse effect, the authors decided normal sinus rhythm or mean heart rate <180 bpm as the primary endpoint in this study.
Question 8
There are a lot of secondary endpoints for a sample size of 50 patients. Response: Each secondary endpoint is important to predict the efficacy and safety of the protocoldefined transplacental treatment of fetal tachyarrhythmias. The authors think that even an excessive number of secondary endpoints cannot directly affect evaluation of the efficacy, because the efficacy is evaluated by primary endpoint. However, the authors must be careful about false positives and robustness of the result. The results are to be interpreted with sufficient attention and sensitivity analysis is conducted as described in paragraph of "Statistical analysis" (page 17, lines 8-9).
Question 9 Define ECG abnl (any abnormality, lengthening of QT with sotalol is normal but there is an acceptable limit) Not sure neonatal adverse event should be an arrhythmia as some infants will go back into SVT after separated from mom and placental therapy and this is expected rather than an adverse outcome from the trial. Response: Regarding ECG abnormality, the authors have added the following sentences (page 8, lines 24-25), "ECG abnormalities are defined as PR prolongation, atrioventricular block, QT prolongation of more than 500 ms, etc." Regarding neonatal tachyarrhythmia, the authors agree the reviewer"s point of view. However, by reviewing the previous reports, the authors felt that small number of information have been available regarding the incidence of postnatal tachyarrhythmia. In addition, there have been no reports if the prenatal treatment changes the incidence of neonatal tachycardia or changes the effectiveness of postnatal antiarrhythmic treatment. Therefore, the authors felt that documenting any abnormal postnatal course is very important in this study, and decided to evaluate neonatal tachyarrhythmia as an adverse event in this study protocol.
Question 10 A lot of leeway with exclusion criteria, P11 line 6 Need to be more specific in describing AV interval measurement. Need to be more specific in descriptions Line 13 belongs in exclusion.
Response: In accordance with the reviewer"s suggestion, the authors have revised the exclusion criteria to be more specific (page 9, line 23-page 10, line 2), "ii) The mother is anticipated to contraindicated to the antiarrhythmic medications, iii) The fetus is diagnosed to have serious and lifethreatening malformations, iv) The fetus is diagnosed with multifocal atrial tachycardia or chaotic atrial tachycardia, v) The mother or fetus is not eligible, in the investigator"s judgment, for this clinical study for reasons other than those above." Question 11 Do the patients have to wait until registration to receive therapy?? How long does this take? Response: Since the secretariat is available 24 hours a day, the patients can usually receive fetal therapy within 3 hours. Therefore, there is no disadvantage for the patients.
Question 12
Confused by page 13, line 6. Does that mean if therapy continues if not effective or in generally? Response: The authors have corrected to the following sentence (page 12, lines 21). "If the investigator continues the fetal therapy beyond 37 gestational weeks even when fetal therapy is not effective, the fetus will be classified as noncompliant."
Question 13 Does the protocol cover adjustments based on dose or are these up to provider discretion? Response: The investigator will proceed to the fetal therapy according to the study protocol. The maintenance doses of digoxin will be adjusted based on maternal blood concentration measurements (range 1.5 to 2.0 ng/mL). The investigator will continue the effective dose of sotalol and flecainide until delivery. However, the investigator will either discontinue the drug or reduce its dose at his or her discretion, if the mother or fetus develops adverse drug reactions to digoxin, sotalol or flecainide.
Question 14
The criteria for delivery seem very nonspecific. If they are measuring premature delivery as an outcome this should be more specific. Response: The criteria for premature delivery are defined in previous paragraphs of "Fetuses unresponsive to fetal therapy" and "Stopping criteria". To clarify this point, the authors have added the following sentences (page 16, lines 13-14), "In non-responded cases, the investigator should deliver the fetuses following the previously described criteria in "fetuses unresponsive to therapy" and "stopping criteria"."
VERSION 2 -REVIEW REVIEWER
Ming-Chih Lin Taichung Veterans General Hospital, Taiwan REVIEW RETURNED 11-Jun-2017
GENERAL COMMENTS
I have no further questions.
